Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 9, 2023

Consolidated Financial Results for the Six Months Ended September 30, 2023 (Under IFRS)

Company name: YUKIGUNI MAITAKE CO., LTD.
Listing: Tokyo Stock Exchange
Securities code: 1375
URL: https://www.maitake.co.jp/
Representative: Masafumi Yuzawa, President and CEO, Representative Director
Inquiries: Takenori Sakurai, Senior Executive Officer (Chief Financial Officer)
Telephone: +81-25-778-0162
Scheduled date to file quarterly securities report: November 10, 2023
Scheduled date of dividend payment commencement November 29, 2023
Preparation of supplementary material on quarterly financial results: Yes
Holding of quarterly financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated Financial Results for the First Six Months Ended September 30, 2023 (from April 1, 2023 to September 30, 2023)

(1) Consolidated Operating Results (Cumulative)

(Percentages indicate year-on-year changes.)

	Total income		Operating profit		Profit before tax		Profit	
Six months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2023	18,806	7.4	1,069	31.3	864	39.2	559	29.3
September 30, 2022	17,513	−14.6	814	-68.1	620	-73.5	432	-71.6

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Six months ended	Millions of yen	%	Millions of yen	%	Yen	Yen
September 30, 2023	559	29.6	565	30.8	14.03	14.03
September 30, 2022	431	-71.6	432	-71.6	10.83	10.83

(Reference)

	Core operating profit		Core EBITDA		Core EBITDA margin
Six months ended	Millions of yen	%	Millions of yen	%	%
September 30, 2023	−179	-	904	−25.8	6.7
September 30, 2022	197	−86.9	1,218	−50.8	9.6

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
September 30, 2023	36,845	10,741	10,741	29.2
March 31, 2023	33,304	10,409	10,409	31.3

2. Cash Dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2023	–	14.00	–	6.00	20.00
Fiscal year ending March 31, 2024	–	1.00			
Fiscal year ending March 31, 2024 (Forecast)			–	1.00	2.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Forecast of Consolidated Financial Results for the Fiscal Year Ending March 31, 2024 (from April 1, 2023 to March 31, 2024)

(Percentages indicate year-on-year changes.)

	Total income		Operating profit		Profit before tax		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Full year	44,467	5.4	1,624	−25.8	1,210	−32.6	780	−34.0

	Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Yen
Full year	780	−33.9	19.58

Note: 1. Revisions from financial results forecasts announced most recently: Yes
2. Please see the "Revision of Full-year Forecast of Consolidated Financial Results for the Fiscal Year Ending March 2024" released today, November 9, 2023.

(Reference)

	Core Operating Profit		Core EBITDA		Core EBITDA Margin
	Millions of yen	%	Millions of yen	%	%
Full year	1,844	−28.0	4,034	−13.5	12.2

*** Notes**

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): Yes
Excluded 1 (Company name) Mitsukura Norin Co., Ltd.
Note: Mitsukura Norin Co., Ltd. was dissolved in an absorption-type merger with the Company as the surviving company as of April 1, 2023.

(2) Changes in accounting policies and changes in accounting estimates
(i) Changes in accounting policies required by IFRS: None
(ii) Changes in accounting policies due to other reasons: None
(iii) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of September 30, 2023	39,910,700 shares
As of March 31, 2023	39,910,700 shares

(ii) Number of treasury shares at the end of the period

As of September 30, 2023	15,067 shares
As of March 31, 2023	27,311 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Six months ended September 30, 2023	39,876,893 shares
Six months ended September 30, 2022	39,870,700 shares

* Quarterly financial results reports are exempt from quarterly review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

(Caution concerning forward-looking statements)

The forward-looking statements, such as forecasts of financial results, included in this document are based on information available to the management as of the date of the document and certain assumptions that the management considers reasonable. The Company does not promise that forecasts will be achieved. Actual results may differ significantly due to a range of factors.

(Other special comments)

(1) The Company and its consolidated subsidiaries (together, "the Group") apply the International Financial Reporting Standards (hereinafter "IFRS").

(2) Core operating profit = Operating profit – IAS41 "Agriculture" applying effects – Other income and expenses – One-time income and expenses

(3) Core EBITDA = Core operating profit + Depreciation + Amortization

(4) Core EBITDA margin = Core EBITDA / Revenue

(5) The effect of applying IAS 41 "Agriculture" is to apply IAS 41 "Agriculture" to the production process of mushrooms, from preparation to harvest, and to measure the mushrooms as biological assets at fair value less costs to sell. The gains or losses from the changes in fair value are considered as the impact amount.

(6) Other income and expenses are mainly impairment losses and loss on disposal of fixed assets.

(7) One-time income and expenses are income and expenses that are not incurred in the normal course of business. There are no one-time income and expenses incurred during the six months ended September 30, 2022 or the six months ended September 30, 2023.

(8) Core operating profit, Core EBITDA and Core EBITDA margin are not indicators defined by IFRS, but the Group assumes these indicators are useful for investors to evaluate the Group's performance. These financial indicators exclude the effect of non-recurring gains / losses and items that do not adequately present the Group's performance relative to its competitors. Core operating profit, Core EBITDA, Core EBITDA margin should not be considered as indicators to replace the other indicators shown in accordance with IFRS because they do not include some of the items that affect the profit for the period, so they are subject to significant restrictions as means of analysis. Core operating profit, Core EBITDA, Core EBITDA margin disclosed by the Group may be less useful in comparison with the same or similar indicators of other competitors because they are calculated according to a different method from those of such other companies.

(How to obtain supplementary financial results briefing materials and financial results briefing details)

The company plans to hold a briefing session for institutional investors and analysts on Monday, December 11, 2023, using a hybrid format of on-site and live streaming.

Supplementary financial results briefing materials are posted on our website on November 9, 2023.

Accompanying Materials – Contents

I. Qualitative Information for the first Six-Month Period of the Fiscal Year Ending March 31, 2024…2

1. Analysis of Operating Results……2

2. Analysis of Financial Position……4

3. Analysis of Cash Flows ……4

4. Explanations about Forward-Looking Information Including Forecast of Consolidated Financial Results…4

II. Summarized Quarterly Consolidated Financial Statements and Significant Notes……5

1. Summarized Quarterly Consolidated Statements of Financial Position……5

2. Summarized Quarterly Consolidated Statements of Income and Comprehensive Income ……7

3. Summarized Quarterly Consolidated Statement of Changes in Equity……9

4. Summarized Quarterly Consolidated Statements of Cash Flows……10

5. Notes to Summarized Consolidated Financial Statements……11

(Going Concern Assumptions) ……11

(Segment Information) ……11

(Earnings per Share) ……12

(Significant Subsequent Events) ……12

I. Qualitative Information for the First Six-Months Period of the Fiscal Year Ending March 31, 2024

1. Analysis of Operating Results

During the first half of the current fiscal year (April 1, 2023 to September 30, 2023), the Japanese domestic economy has been experiencing a normalization of economic activity due to a change in the legal status of COVID-19. On the other hand, price hikes for food products and daily necessities have not abated against the unstable international situation due to Russia's invasion of Ukraine with no end in sight, soaring energy prices, higher procurement prices due to the yen's depreciation, and increased labor costs due to a shortage of human resources, and consumers are still highly economical in their daily consumption activities.

In such an economic environment, the Group has also been facing a situation where various cost increases have put pressure on profits, such as raw material price hikes and utility costs remaining at high levels, etc. However, each department has worked together to mitigate the impact of cost increases by optimizing procurement of raw materials and packaging materials and by improving production efficiency. In terms of sales, the Company maintained a higher unit sales price level than in the same period of the previous year by proposing optimal products tailored to each region and store and by effectively utilizing multiple product lineup development. In addition, mainly white maitake is used in convenience stores and retail side dish menus, as well as in high-end restaurants, in an effort to raise awareness as a premium mushroom.

In accordance with its medium-term business plan, the Group is working to establish a foundation as a comprehensive premium mushroom manufacturer by leveraging the Company's production technology, know-how, and sales capabilities that have been cultivated over the years. In addition to this, we have developed and promoted the functional properties of mushrooms, especially maitake mushrooms, to contribute to the health of consumers through the provision of safe and secure products and to develop our business in order to contribute to the realization of a healthy society.

As announced in the "New Business Development (Alternative Meat)" dated June 20, 2023, the Company has successfully developed alternative meat using mushrooms as the main ingredient.

While the current alternative meat market is dominated by products made primarily from soy-derived ingredients, the product we have developed is a new health-conscious product that takes advantage of the low calorie, low fat, and dietary fiber characteristics of the mushrooms used as ingredients, while pursuing a natural taste. Also, since the main ingredient is our mushrooms produced under strict quality control, we believe the product will be widely supported from the standpoint of food safety. We will continue to leverage our unique strengths as a mushroom manufacturer to engage in various types of new businesses.

Total income for the second quarter of the current consolidated cumulative period was ¥18,806 million (+7.4% year-on-year), of which revenue was ¥13,457 million (+5.5% year-on-year). Gross profit was ¥4,953 million (+9.9% year-on-year). Selling, general and administrative (SG&A) expenses were ¥3,871 million (+5.5% year-on-year).

As a result of the above, operating profit was ¥1,069 million (+31.3% year-on-year) and profit attributable to owners of the parent was ¥559 million (+29.6% year-on-year). In the current consolidated cumulative period, gains arising from changes in fair value related to the application of IFRS Agricultural Accounting (IAS 41) were included in total income of ¥5,349 million (+12.5% year-on-year) and the cost of sales of ¥3,885 million (-1.9% year-on-year), respectively.

[Business results for the six months ended September 30, 2023]

(Millions of yen)

	Six months ended September 30, 2022	Six months ended September 30, 2023	% Change year-on-year
Revenue	12,757	13,457	5.5
Gains arising from changes in fair value	4,755	5,349	12.5
Total income	17,513	18,806	7.4
Operating profit	814	1,069	31.3
Profit before tax	620	864	39.2
Profit attributable to owners of parent	431	559	29.6

The status of revenue by business segment during the current consolidated fiscal year is as follows.

[Mushroom business]

1) Maitake

Aiming to further expanding demand for maitake, we are working on sales measures that take advantage of our extensive product lineup, which is one of our strengths. Among them, "Yukiguni Maitake Kiwami White", which was launched last fall, received favorable reviews for its beautiful appearance and freshness, as well as for its introduction to salad menus such as caprese to increase awareness as to how to eat it. As a result, sales volume decreased compared to the same period of the previous year, but unit sales prices remained strong. Thus, revenue of the Maitake business was ¥7,257 million (+2.9% year-on-year).

2) Eringi

The Company maintains supply volume through stable production quality and offers a variety of products, such as convenient large quantity sliced products, in addition to our standard tray products of various quantities. As a result, both sales volume and unit sales prices were significantly higher than those in the same period of the previous year. Thus, revenue of the Eringi business was ¥1,700 million (+20.3% year-on-year).

3) Buna-shimeji

While keeping a close eye on the fruit and vegetable market and market trends, we flexibly switch the products sales mix with different quantities according to the supply-demand balance and implement a stable supply. As a result, sales volume was almost the same as in the same period of the previous year, but unit sales prices remained strong. Thus, revenue from the Buna-shimeji business was ¥2,832 million (+12.1% year-on-year).

4) Other mushrooms

In Button mushrooms, sales remained the same as in the same period of the previous year due to efforts to strengthen business synergies through absorption-type mergers, stabilize production conditions, and improve quality. In addition, sales of Hatake-shimeji remained steady. On the other hand, sales volume of Hon-shimeji remained sluggish compared to the same period of the previous year due to a temporary instability in production that prevented us from meeting demand. As a result of the above, revenue from other mushroom businesses was ¥1,519 million (-3.4% year-on-year).

[Other]

Revenue from the “Other” business is mainly derived from sales of health foods and sales of culture medium activators handled by Mizuho Norin Co., Ltd. In the first quarter of the current consolidated fiscal year, sales volume of health foods, and production and sales volume of culture medium activators decreased, respectively. As a result, revenue from other businesses was ¥146 million (-23.5% year-on-year).

Revenue by business segment is as follows.

(Millions of yen)

	Six months ended September 30, 2022	Six months ended September 30, 2023	% Change year-on-year
Mushroom business	12,566	13,310	5.9
Maitake	7,051	7,257	2.9
Eringi	1,413	1,700	20.3
Buna-shimeji	2,526	2,832	12.1
Other mushrooms	1,573	1,519	(3.4)
Other	191	146	(23.5)
Total Revenue	12,757	13,457	5.5

2. Analysis of Financial Position

[Assets]

Total assets at the end of the second quarter of the current consolidated fiscal year (as of September 30, 2023) were ¥36,845 million (+¥3,540 million from the end of the previous consolidated fiscal year). Current assets were ¥10,614 million (+¥3,434 million from the end of the previous consolidated fiscal year). This was mainly due to an increase of ¥704 million in cash and cash equivalents, ¥1,124 million in trade and other receivables and ¥1,558 million in biological assets due to gains arising from changes in fair value, respectively. Non-current assets were ¥26,230 million (+¥106 million from the end of the previous consolidated fiscal year). This was mainly due to a ¥119 million increase in property, plant and equipment.

[Liabilities]

Total liabilities at the end of second quarter of the current consolidated fiscal year were ¥26,104 million (+¥3,208 million from the end of the previous consolidated fiscal year). This was mainly due to increases of ¥15,440 million in current portion of long-term borrowings, ¥2,300 million in short-term borrowings and ¥2,132 million in trade and other payables, while decreases of ¥386 million in income taxes payable, ¥336 million in other liabilities including accrued expenses and accrued consumption taxes, respectively. Non-current liabilities were ¥231 million (-¥16,070 million). This was mainly due to a decrease of ¥16,070 million in borrowings, mainly due to a transfer to current portion of long-term borrowings.

[Equity]

Total equity at the end of second quarter of the current consolidated fiscal year was ¥10,741 million (+¥331 million from the end of the previous consolidated fiscal year). This was mainly due to an increase of ¥320 million in retained earnings resulting from the recording of a quarterly profit.

3. Analysis of Cash Flows

The balance of cash and cash equivalents at the end of the second quarter of the current consolidated fiscal year increased by ¥704 million from the end of the previous consolidated fiscal year to ¥1,764 million. The status of each cash flow and their factors are as follows:

[Net cash flows from operating activities]

The amount of funds used as a result of operating activities was ¥139 million (the amount used was ¥1,383 million in the same period of the previous year). This was mainly due to income before income taxes of ¥864 million, depreciation and amortization of ¥1,089 million, and an increase in trade and other payables of ¥1,207 million, while there was an increase in trade and other receivables of ¥1,124 million, an increase in biological assets of ¥1,558 million, and income taxes paid of ¥691 million.

[Net cash flows from investing activities]

Funds used as a result of investment activities were ¥341 million (the amount used was ¥1,715 million in the same period of the previous year). This was mainly due to the expenditure of ¥329 million for the acquisition of renewed property, plant and equipment related to production of mushrooms.

[Net cash flows from financing activities]

Funds provided as a result of financing activities were ¥1,185 million (the amount provided was ¥75 million in the same period of the previous year). This was mainly due to proceeds from short-term borrowings of ¥2,300 million, repayment of long-term borrowings of ¥770 million due to scheduled repayments, and cash dividends paid of ¥239 million.

4. Explanations about Forward-Looking Information Including Forecast of Consolidated Financial Results

For the full-year forecasts of the consolidated financial results for the fiscal year ending March 2024, please see the “Revision of Full-year Forecast of Consolidated Financial Results for the Fiscal Year Ending March 2024” released today, November 9, 2023.

The earnings forecast is based on the information available at this time, and the actual financial results may differ due to various factors.

II. Summarized Quarterly Consolidated Financial Statements and Significant Notes

1. Summarized Quarterly Consolidated Statements of Financial Position

(Millions of yen)

	As of March 31, 2023	As of September 30, 2023
Assets		
Current assets		
Cash and cash equivalents	1,060	1,764
Trade and other receivables	1,907	3,032
Inventories	1,422	1,498
Biological assets	2,662	4,220
Income taxes receivable	21	-
Other current assets	105	98
Total current assets	7,180	10,614
Non-current assets		
Property, plant and equipment	18,966	19,086
Investment property	95	95
Goodwill and intangible assets	5,285	5,276
Right-of-use assets	238	216
Retirement benefit asset	313	317
Other financial assets	191	207
Deferred tax assets	990	988
Other non-current assets	42	42
Total non-current assets	26,124	26,230
Total assets	33,304	36,845

(Millions of yen)

	As of March 31, 2023	As of September 30, 2023
Liabilities		
Current liabilities		
Trade and other payables	1,877	4,010
Income taxes payable	693	306
Employee benefit accruals	1,683	1,899
Short-term borrowings	-	2,300
Current portion of long-term borrowings	1,509	16,949
Lease liabilities	152	133
Provisions	140	0
Other financial liabilities	21	93
Other current liabilities	515	178
Total current liabilities	6,592	25,872
Non-current liabilities		
Borrowings	16,070	-
Lease liabilities	156	157
Provisions	20	20
Other financial liabilities	54	54
Other non-current liabilities	0	0
Total non-current liabilities	16,302	231
Total liabilities	22,895	26,104
Equity		
Share capital	100	100
Capital surplus	(6,012)	(6,022)
Retained earnings	16,341	16,661
Treasury shares	(33)	(17)
Other components of equity	14	19
Total equity attributable to owners of parent	10,409	10,741
Non-controlling interests	(0)	(0)
Total equity	10,409	10,741
Total liabilities and equity	33,304	36,845

2. Summarized Quarterly Consolidated Statements of Income and Comprehensive Income

(Summarized Quarterly Consolidated Statements of Income)

(Millions of yen)

	Six months ended September 30, 2022	Six months ended September 30, 2023
Income		
Revenue	12,757	13,457
Gains arising from changes in fair value	4,755	5,349
Total income	17,513	18,806
Cost of sales (*1)	13,004	13,852
Gross profit	4,508	4,953
Selling, general and administrative expenses	3,668	3,871
Other income	32	39
Other expenses	57	51
Operating profit	814	1,069
Finance income	6	2
Finance expenses	200	208
Profit before tax	620	864
Income tax expense	188	304
Profit	432	559
Profit attributable to		
Owners of parent	431	559
Non-controlling interests	0	-
Earnings per share		
Basic earnings per share (Yen)	10.83	14.03
Diluted earnings per share (Yen)	10.83	14.03

Management believes that the information of “material costs, labor costs, etc.” facilitates comparison between the Group and competitors by users of financial statements. Therefore, we disclose the information voluntarily as a note in the summarized consolidated statements of income. “Material costs, labor costs, etc.” are the production costs of finished goods and purchasing costs of other goods sold by the Group, excluding the gains arising from changes in fair value recognized under IAS 41 “Agriculture”.

(*1) Components of cost of sales		
Material costs, labor costs, etc.	9,045	9,967
Gains arising from changes in fair value	3,959	3,885
Total	13,004	13,852

(Summarized Quarterly Consolidated Statements of Comprehensive Income)

(Millions of yen)

	Six months ended September 30, 2022	Six months ended September 30, 2023
Profit	432	559
Other comprehensive income (After tax effect deduction)		
Items that will not be reclassified to profit or loss		
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income	(0)	5
Total of items that will not be reclassified to profit or loss	(0)	5
Total other comprehensive income (After tax effect deduction)	(0)	5
Comprehensive income	432	565
Comprehensive income attributable to		
Owners of parent	431	565
Non-controlling interests	0	-

3. Summarized Quarterly Consolidated Statement of Changes in Equity

Six months ended September 30, 2022 (From April 1, 2022 to September 30, 2022)

(Millions of yen)

	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity	Total equity attributable to owners of parent	Non-controlling interests	Total
Balance at beginning of period	100	(6,006)	16,411	(48)	15	10,471	(1)	10,470
Profit	-	-	431	-	-	431	0	432
Other comprehensive income	-	-	-	-	(0)	(0)	-	(0)
Comprehensive income	-	-	431	-	(0)	431	0	432
Share-based remuneration transactions	-	(12)	-	15	-	3	-	3
Dividends of surplus	-	-	(637)	-	-	(637)	-	(637)
Transfer from other components of equity to retained earnings	-	-	1	-	(1)	-	-	-
Total	-	(12)	(636)	15	(1)	(634)	-	(634)
Balance at end of period	100	(6,018)	16,207	(33)	12	10,268	(0)	10,268

Six months ended September 30, 2023 (From April 1, 2023 to September 30, 2023)

(Millions of yen)

	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity	Total equity attributable to owners of parent	Non-controlling interests	Total
Balance at beginning of period	100	(6,012)	16,341	(33)	14	10,409	(0)	10,409
Profit	-	-	559	-	-	559	-	559
Other comprehensive income	-	-	-	-	5	5	-	5
Comprehensive income	-	-	559	-	5	565	-	565
Share-based remuneration transactions	-	(9)	-	15	-	5	-	5
Dividends of surplus	-	-	(239)	-	-	(239)	-	(239)
Transfer from other components of equity to retained earnings	-	-	-	-	-	-	-	-
Total	-	(9)	(239)	15	-	(233)	-	(233)
Balance at end of period	100	(6,022)	16,661	(17)	19	10,741	(0)	10,741

4. Summarized Quarterly consolidated Statements of Cash flows

(Millions of yen)

	Six months ended September 30, 2022	Six months ended September 30, 2023
Cash flows from operating activities		
Profit before tax	620	864
Depreciation and amortization	1,027	1,089
Interest expenses	191	199
Commission for syndicate loan	8	8
Loss (gain) on sale of fixed assets	(0)	(1)
Loss on retirement of fixed assets	40	38
Decrease (increase) in trade and other receivables	(282)	(1,124)
Decrease (increase) in inventories	(279)	(75)
Decrease (increase) in biological assets	(984)	(1,558)
Increase (decrease) in trade and other payables	259	1,207
Decrease (increase) in retirement benefit asset	(1)	(4)
Increase (decrease) in employee benefit liabilities	38	216
Other	(495)	(261)
Subtotal	144	597
Interest paid	(42)	(59)
Payments of commission for syndicate loan	(9)	(8)
Income taxes paid	(1,475)	(691)
Income taxes refund	-	21
Net cash provided by (used in) operating activities	(1,383)	(139)
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,692)	(329)
Proceeds from sale of property, plant and equipment	0	1
Purchase of intangible assets	(11)	(0)
Other	(11)	(13)
Net cash provided by (used in) investing activities	(1,715)	(341)
Cash flows from financing activities		
Proceeds from short-term borrowings	1,500	2,300
Repayments of long-term borrowings	(674)	(770)
Repayments of lease liabilities	(113)	(105)
Dividends paid	(637)	(239)
Other	(0)	-
Net cash provided by (used in) financing activities	75	1,185
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	(3,023)	704
Cash and cash equivalents at beginning of period	3,723	1,060
Decrease in cash and cash equivalents resulting from exclusion of subsidiaries from consolidation	(0)	-
Cash and cash equivalents at end of period	699	1,764

5. Notes to Summarized Consolidated Financial Statements

(Going Concern Assumptions)
Not applicable.

(Segment Information)

(1) Reportable segments

The Group's reportable segments are components of the Group for which separate financial information is available and regular evaluation by the Board of Directors, chief operating decision maker, is being performed in order to make decisions about resources to be allocated and to assess its performance.

The mushroom business is listed as a reporting segment as the Group has a comprehensive strategy for products and services and is expanding its business activities. "Other" includes businesses that are not included in the reportable segment.

The Group aggregates Maitake business, Eringi business, Buna-shimeji business, etc. as a reportable segment, "mushroom business," in terms of similarity of economic characteristics such as revenue trends, and the following features are all similar in this segment: (a) the nature of products and services, (b) the nature of the production processes, (c) the type of customers of the products and the services, (d) the method used to deliver the products or provide the services, and (e) the nature of regulatory environment.

Description of the reportable segment is as follows:

	Description of business
Mushroom business	Production and sales of Maitake, Eringi, Buna-shimeji and other mushrooms

(2) Reportable segments information

The accounting methods of reportable business segments are the same as the Group's accounting policies. Figures reported as segment profit are based on operating profit reported in the summarized consolidated statements of income. Revenues from intersegment transactions are based on the current market prices.

Six months ended September 30, 2022 (From April 1, 2022 to September 30, 2022) (Millions of yen)

	Mushroom business	Others	Total	Adjustment items (*1)	Per consolidated financial statements
Revenue					
Revenue from external customers	12,566	191	12,757	-	12,757
Intersegment revenue	-	-	-	-	-
Total revenue	12,566	191	12,757	-	12,757
Segment profit	790	22	812	2	814
Finance income					6
Finance expenses					200
Profit before tax					620

(*1) Adjustment items for segment profit include corporate expenses that are not allocated to each business segment.

Six months ended September 30, 2023 (From April 1, 2023 to September 30, 2023) (Millions of yen)

	Mushroom business	Others	Total	Adjustment items (*1)	Per consolidated financial statements
Revenue					
Revenue from external customers	13,310	146	13,457	-	13,457
Intersegment revenue	-	-	-	-	-
Total revenue	13,310	146	13,457	-	13,457
Segment profit (loss)	1,060	19	1,080	(10)	1,069
Finance income					2
Finance expenses					208
Profit before tax					864

(*1) Adjustment items for segment profit (loss) include corporate expenses that are not allocated to each business segment.

(Earnings per Share)

Calculation of basic earnings per share and diluted earnings per share are described below.

	(Unit)	Six months ended September 30, 2022	Six months ended September 30, 2023
Basic earnings per share			
Profit attributable to owners of parent	(Millions of yen)	431	559
Profit not attributable to common shareholders of parent	(Millions of yen)	-	-
Profit used for calculation of basic earnings per share	(Millions of yen)	431	559
Average number of common shares during the period	(Thousand shares)	39,870	39,876
Basic earnings per share	(Yen)	10.83	14.03
Diluted earnings per share			
Profit used for calculation of basic earnings per share	(Millions of yen)	431	559
Adjustment	(Millions of yen)	-	-
Profit used for calculation of diluted earnings per share	(Millions of yen)	431	559
Average number of common shares during the period	(Thousand shares)	39,870	39,876
Increase of shares due to restricted stock compensation plan	(Thousand shares)	1	1
Average number of common shares during the period after dilution	(Thousand shares)	39,872	39,878
Diluted earnings per share	(Yen)	10.83	14.03

(Significant Subsequent Events)

Not applicable.